Summary
This prediction is currently active. The prediction for Evotec SE shows a convincing performance of -24.69%. This prediction currently runs until 21.07.25. The prediction end date can be changed by WatchMen at any time. WatchMen has 50% into this predictionEvotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Evotec SE | 20.495% | 20.495% |
iShares Core DAX® | 1.937% | 1.473% |
iShares Nasdaq 100 | -1.186% | -0.040% |
iShares Nikkei 225® | 1.938% | 4.205% |
iShares S&P 500 | -0.023% | 0.109% |
Comments by WatchMen for this prediction
In the thread Evotec AG diskutieren